摘要
目的探讨滋阴活血方治疗儿童糖尿病的临床疗效。方法选取医院2015年12月至2016年12月收治的糖尿病患儿90例,采用随机数字表法分为观察组与对照组,各45例。对照组患儿给予常规西医治疗,观察组患儿在此基础上加用滋阴活血方。结果观察组总有效率为93.33%,显著高于对照组的77.78%(P<0.05);观察组患儿治疗后的空腹血糖(FBG)为(6.41±0.32)mmol/L,餐后2 h血糖(2 h PG)为(10.01±0.36)mmol/L,糖化血红蛋白(Hb A1C)为(6.13±0.48)%,总胆固醇(TC)为(4.11±0.67)mmol/L,三酰甘油(TG)为(1.47±0.23)mmol/L,肿瘤坏死因子-α(TNF-α)为(192.41±12.78)ng/L,基质金属蛋白酶-3(MMP-3)为(102.56±6.62)ng/m L,显著低于对照组的(6.89±0.37)mmol/L,(11.66±0.42)mmol/L,(6.78±0.36)%,(4.36±0.62)mmol/L,(1.61±0.27)mmol/L,(225.67±13.78)ng/L,(127.32±4.89)ng/m L(P<0.05)。结论滋阴活血方能降低糖尿病患儿血糖、血脂水平,减少肾损伤,改善肾功能,临床疗效显著,值得推广。
Objective To investigate the clinical effect of Ziyin Huoxue Recipe for treating children patients with diabetes mellitus. Methods Totally 90 children patients with diabetes mellitus admitted to our hospital from December 2015 to December 2016 were selected and divided into the observation group and the control group by random number table method,45 cases in each group. The control group was given conventional Western medicine, on this basis, the observation group was given Ziyin Huoxue Recipe. Results The total eftctive rate in the observation group was 93.33% ,which was significantly higher than 77.78% in the control group （P 〈 0.05）. After treatment,the FBG was （6.41 ± 0.32）retool/L;2 hPG was （10. 01 ± 0.36）retool/L, HbAlc was （6.13 ± 0. 48）% ,TC was （4.11 ± 0. 67）mmol/L,TG was （1.47 ± 0.23）mmol/L,TNF - α was （192. 41 ± 12. 78）ng/L,MMP -3 was （102.56 ± 6. 62）ng/mL in the observation group, which were significantly lower than （6. 89 ± 0.37） retool/L, （11.66 ± 0. 42） retool/L, （6.78 ± 0.36）% , （4. 36±0.62）retool/L,（1.61 ±0.27）mmol/L,（225.6±13.？8）ng/L,（127.32±4.89）ng/mL in the control group（P 〈 0.05）. Conclusion Ziyin Huoxue Recipe can reduce levels of blood sugar and blood lipid,reduce renal injury and improve renal function in children with diabetes mellitus,it is worthy of promotion.
作者
王建军
赵德运
张剑霄
刘玲
刘艳辉
Wang Jianjun;Zhao Deyun;Zhang Jianxiao;Liu Ling;Liu Yanhui(Department of Pharmacy, Hebei Children＇ s Hospital, Shijiazhuang, Hebei, China 05003)
出处
《中国药业》
CAS
2018年第8期30-32,共3页
China Pharmaceuticals
基金
2017年度河北省医学科学研究重点课题计划项目[201613b1501315a]
